Please provide your email address to receive an email when new articles are posted on . Corneal tissue addition keratoplasty, or CTAK, is a novel intrastromal lamellar keratoplasty technique for the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Epion Therapeutics has initiated its phase 3 Apricity ...
BURLINGTON, Mass.--(BUSINESS WIRE)--Epion Therapeutics (Epion) announced the commencement of its Phase 3 Apricity trials for EpiSmart™, the company’s minimally-invasive keratoconus therapy. This marks ...
Keratoconus is a progressive eye condition that affects the shape and clarity of the cornea, often beginning in the teenage years or early adulthood. As the cornea thins and bulges into a cone-like ...
On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...
Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal ...
Glaukos (GKOS) announced the submission of its New Drug Application NDA to the U.S. Food and Drug Administration FDA or Epioxa or Epi-on, its next-generation corneal cross-linking iLink therapy for ...
Two surgical procedures have been described for ICRS implantation: the mechanical method and the femtolaser method. The use of femtolaser for ICRS tunnel creation was widely accepted after FDA ...
SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a ...
Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for ...
The average per-person inflation-adjusted lifetime cost of keratoconus treatment in 2019 was nearly $29,000, with a cumulative economic burden of $3.8 billion, a large retrospective cohort study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results